Visikol Multiplex Grant Program

We are pleased to announce that between now and June 30th, 2021, Visikol will be accepting abstract submissions for free multiplex tissue imaging services.

We will be providing labeling and imaging of five slides to five different researchers as part of this initiative using one of the three pre-validated panels below. If selected, just send along your slides and we will share with your beautiful multiplex high resolution slide images using our BitSlide cloud-based slide sharing platform.

Interested in applying for free multiplex tissue imaging services?

Submit

T-Cell Activation Panel

Memory T Cell Panel

Antigen Presenting Cell Panel

DAPI (Blue), PanCK (Cyan), CD3 (Green), Granzyme b (Red) and Ki67 (Yellow)

Tissue samples are labelled for CD3-a T cell receptor protein and granzyme b, a serine protease that is primarily secreted by cytotoxic CD8+ T cells and NK cells. Activated T cell are positive for both CD3 and granzyme b and tumor tissue is positively labelled for pan-cytokeratin. Ki67 marks regions of the tumor that are actively proliferating.

DAPI (Blue), PD-1 (Green), PanCK (Cyan), CD3 (Red), CD45 RO (Yellow)

This panel labels CD45RO which marks memory T cells and exhausted T cells are labelled for PD-1. This panel also labels, CD3 a pan T cell marker and pan cytokeratin that labels tumor cells. The presence of double positive CD45RO and CD3 T cells in the tumor microenvironment would indicate a favorable adaptive immune response compared to the presence of double positive PD-1 and CD3 T cells that represents an immunosuppressed T cell population.

DAPI (Blue), CD68 (Green), MHCII (Red), CD20 (Yellow)

CD68 that labels resident macrophages, CD20 that labels B cells and MHCII that labels professional antigen presenting cells. Dendritic cells are considered the most powerful antigen presenting cells and their presence in the tumor microenvironment is favorable to mounting an adaptive immune response against tumor cells. Dendritic cells bind tumor neoantigens and present them along with MHCII molecules to T cells.

Want to learn more about our multiplexing approach?

Get additional information on the Visikol Multiplex Immunofluorescence (vmIF) approach

Learn More
2021-04-23T07:40:58-05:00
This website uses cookies to enhance the user experience. Ok